Mumbai-based Glenmark Pharmaceuticals announced that its subsidiary Glenmark Specialty received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small molecule, GRC 54276. It also plans to file an Investigational New Drug program in the U.S. along...